Icagen (ICGN) Senicapoc Fails In Phase IIa Study
Up)
Icagen, Inc. (Nasdaq: ICGN) reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes.
In this double blind placebo-controlled study, 69 patients were randomized to receive either senicapoc at a maintenance dose of 40 mg/day or placebo. All subjects were tested for pulmonary function following a standardized treadmill exercise regimen at baseline, two and four weeks after treatment. The results of the pulmonary function tests were compared between the treatment groups, adjusting for differences in baseline values.
Although the Company will continue to evaluate the data from this trial, it does not anticipate continuing clinical development of senicapoc at this time.
In this double blind placebo-controlled study, 69 patients were randomized to receive either senicapoc at a maintenance dose of 40 mg/day or placebo. All subjects were tested for pulmonary function following a standardized treadmill exercise regimen at baseline, two and four weeks after treatment. The results of the pulmonary function tests were compared between the treatment groups, adjusting for differences in baseline values.
Although the Company will continue to evaluate the data from this trial, it does not anticipate continuing clinical development of senicapoc at this time.
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary Endpoint; to Move Forward with End of Phase Meeting
Create E-mail Alert Related Categories
FDA, Hot ListSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
